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Introduction: The Bellagio II Summit sought to correlate current ISS Space Medicine practice in the 
screening/assessment and management of CAD and to identify terrestrial applications for the general 
population pertaining to primary, secondary and tertiary diagnoses and treatments. We identified 
current Space Medicine practice for screening and monitoring cosmonaut and astronaut in the pre-, in-, 
and post-flight mission phases. We will discuss current Space Medicine standards and guidelines in the 
recognition and monitoring of CAD development, stabilization, and regression.  
 
Methods: We reviewed current Space Medicine standards, medical records, expert panels, and available 
literature for monitoring of cardiovascular health in astronauts and cosmonauts during ISS selection, 
mission operations, post spaceflight, and lifetime surveillance.  
 
Results: Space Medicine utilizes a number of CAD screening techniques to identify subtle and cumulative 
changes to cardiovascular health. Cardiovascular screening efforts include review of family history, use 
of risk-stratification scores, exercise stress testing, echocardiography, biomarkers, and standard 
hemodynamic clinical monitoring. Further, astronauts and cosmonauts undergo regular monitoring of 
coronary artery calcium (CAC) scores, carotid intimal media thickness (CIMT) measurements, and 
cardiovascular angiographic imaging techniques if clinically indicated. To date, there have been 16 
individuals diagnosed with asymptomatic CAD with anatomic calcium scoring. These individuals 
underwent risk stratification for ISS mission selection/qualification and lifetime surveillance and will be 
discussed. 
 
Discussion: ISS Space Medicine monitoring techniques address the numerous screening tools that 
indicate overall coronary health for astronauts and cosmonauts. Accumulated data provides an 
integrated awareness of CAD and its management and will be presented. Many of these techniques can 
be applied to the terrestrial population for primary, secondary, and tertiary screening, monitoring, and 
treatment of CAD.  
 
LEARNING OBJECTIVES: 
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1.            Understand the development of the MMOP CAD primary, secondary, and tertiary guidelines for 
ISS Missions. 
2.            Understand the risk assessments for CAD and ISS mission qualification.  
3.            Understand the pathophysiology for CAD plaque development, stabilization, and regression. 
 
MOC QUESTIONS: 
Question 1 
CAC Scores above 100 in astronauts/cosmonauts require angiographic analysis for luminal 
lesions.  (True/False)   
Answer:  True    
 
Question 2 
What is the risk number for CAD to be qualified for an ISS mission?  
A.      < 5 % per year, B. < 0.5 % per year, C. < 10 % per year  
Answer:  B    
 
Question 3 
Can CAD be stabilized and or reversed by risk modifications with diet, exercise, and 
medications?  (True/False) 
Answer: True 
 
